Exhibit 10.35 


 


CONSULTING AGREEMENT


 


THIS CONSULTING
AGREEMENT (the "Agreement") is made and entered into by and between VIRAL GENETICS, INC., a Delaware corporation
(the "Client"), and M. Karen Newell Rogers, ("Consultant") effective the 1st day of January 2011.


 


(the Client and Consultant are jointly referred to herein as
the "Parties")


 


WHEREAS, Consultant
and Client are party to a Consulting Agreement dated July 1, 2007, as amended and extended (the "Old Agreement") and
desire to replace it with a new agreement; and


 


WHEREAS, Client
is a Client engaged in the business of developing and distributing biomedical products and technology; and


 


WHEREAS, Consultant has been engaged in and
has experience in the Client's business; and


 


WHEREAS, the Client desires
to provide for the engagement of Consultant, to clearly set forth the relationship between the parties, and to restrict Consultant
from using certain confidential information and from competing with the Client in the future.


 


NOW THEREFORE,
for good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the Parties agree as follows.


 


1)Non-Exclusive Engagement of Consultant;
Term. Except with respect to those Sections of the Old Agreement intended to survive termination, including, without limitation,
Sections 8(c) and 12, the Old Agreement is hereby terminated, superceded and replaced with this Agreement. All compensation due
or paid to Consultant under the Old Agreement, including without limitation, salary, royalties or options, shall remain earned
and due to Consultant. The Client hereby engages Consultant as its non-exclusive provider of the consulting services described
in this Agreement, for a term (the "Term") which will commence on the date of this Agreement and end December 31, 2015.


 


2)Consultant Services. On the
terms and conditions set forth in this Agreement, Consultant will provide the following services to the Client as directed by
the Client (the "Services"). To facilitate the performance of her duties, Employee shall be designated "Chief Scientific
Advisor", provided that Consultant shall not be granted any of the rights, duties or privileges of an officer or executive
of Client.


 


		a)	Consultant will advise and assist the Client with the worldwide development, evaluation, analysis,
testing, research, and study of its technology and products;



		b)	Consultant will design, manage and analyze studies of the Client's technology and products, including
sourcing and recommending independent facilities as necessary;
	 	c)	Consultant will assist Client in the drafting and review of any documents necessary to obtain or maintain patent protection
of its technology and products or Consultant Creations (as hereinafter defined in Exhibit D);
	 	d)	Consultant shall advise and assist the Client with respect to the authorship, presentation and publication of reports, results,
analyses, studies and other scientific and medical activities of the Client, in recognized peer-reviewed literature or industry
conferences, as mutually agreed to, and review, edit and provide comment on any manuscripts or abstracts relating to its technology
and products, whether authored by Consultant or not, provided they relate to her areas of expertise;



 






    	1



    	 



    

 


		e)	Consultant shall from time to time and as requested present on behalf of the Client in the areas
of its technology and products, its development and scientific strategy, and other areas where Consultant has expertise, including,
without limitation, to the Client's advisory board and investors;



		f)	Consultant will assist and advise the Client in the preparation, review, discussions, follow-up,
and other areas in Client dealings with the FDA, EMEA, and other regulatory agencies in connection with seeking permission for
clinical trials, regulatory approvals, drug and device registration, and other development activities;



		g)	Consultant will advise and assist the Client on other medical issues with respect to the Client's
products and drug candidates; and



		h)	Consultant will assist and advise the Client in other areas in which Consultant has expertise as
reasonably requested from time to time by the Client.



 


Services shall not
(i) involve any use of the facilities, space, materials or other resources of the academic institution at which Consultant is then
employed ("Institution") (provided that use alone by the Consultant of the Consultant's office space, phone, email, computer,
word processor and similar assets shall not be considered a prohibited use of Institution's resources), or (ii) use direct or indirect
financial support from Institution, including funding from any outside source awarded to or administered by Institution. Notwithstanding
anything to the contrary in this Agreement, nothing in this Agreement shall be construed to restrict or limit the duties Consultant
is performing or may perform in the course of, or incidental to, Consultant's appointment at Institution.


 


3)Method of Providing Services.
Consultant shall be available for a teleconference meeting with the management of the Client at least twice per month during the
Term. Consultant will perform Services, and may communicate with the Client's management and other parties, through personal meetings,
correspondence, telephone or video conferences, and such other methods, and at such times, as mutually determined, subject to the
reasonable convenience of the parties. Unless requested otherwise by the Client, Consultant shall communicate with the Client's
management through the Client's President. Acting in good faith and consistent with ordinary business practices with respect to
advisory relationships, Consultant shall devote a reasonable amount of time per month to the provision of the Services described
herein provided that this does not materially conflict with Consultant's appointment at Institution.


 


4)Performance. Consultant agrees
to at all times faithfully, industriously, and to the reasonable best of her abilities, experience, and talents, perform all of
the Services that may be required of and from her pursuant to the express and explicit terms hereof.


 


5)Independence of Parties. Nothing
contained in this Agreement shall constitute either party as an employee, partner, co-venturer or agent of the other, it being
intended that each shall act as an independent contractor with respect to the other. Consultant is not authorized to speak on behalf
of the Client or bind it in any manner.


 


6)Compensation. 


 


		a)	Fees. For and in consideration of the agreement of Consultant to enter into and perform
under this Agreement, the Client shall pay to Consultant $10,000 per month (the "Fee"). Earned but unpaid Fees due hereunder
shall automatically and without a requirement for notice or consent by either party accrue under the Convertible Note attached
hereto as Exhibit A.



		b)	Options. For and in consideration of the agreement of the Consultant to enter into this
Agreement and as an incentive for the Consultant to use his best efforts in pursuit of the Client's business, concurrently with
the execution of this Agreement the Client and Consultant shall enter into an option agreement for a bonus
of 10,000,000 options, in the form attached hereto as Exhibit B (the "Initial Option"), provided that the exercise price
shall be determined as set forth in this paragraph. On each annual anniversary during the Initial Term and each subsequent one-year
extension period as described in paragraph 5, if any, Client shall grant an additional option of similar tenor but in an amount
equal to not less than 2,500,000 options (each an "Annual Option"). The exercise price of the Initial Option shall be
equal to the volume weighted average price ("VWAP") for the twenty trading days immediately following the actual date
of execution of this Agreement. The exercise price of each Annual Option thereafter shall be equal to the VWAP for the twenty (20)
trading days commencing January 1 of each such year.






 






    	2



    	 



    

 


	 	c)	Royalty.
                                                                                   Consultant shall receive Three Fourths
                                                                                   One Percent (0.75%) of Net Sales from sales
                                                                                   in developed countries, and One Half Percent
                                                                                   (0.125%) from sales in undeveloped countries.
                                                                                   "developed countries" are herein
                                                                                   defined as United States of America, Canada,
                                                                                   Western and Eastern Europe, Japan, Australia,
                                                                                   New Zealand, Israel, Russia, and other countries
                                                                                   of the former Soviet Union, Hong Kong, Singapore,
                                                                                   South Korea, and Taiwan. "Undeveloped
                                                                                   countries" are herein defined as countries
                                                                                   other than developed countries. If any such
                                                                                   Net Sales are due to receipts for sales of
                                                                                   Licensed Products or practice of Licensed Processes
                                                                                   where there is more than one inventor, then
                                                                                   the amount that Consultant shall receive hereunder
                                                                                   shall be proportionately reduced. "Net
                                                                                   Sales" and associated terms are as defined
                                                                                   in Exhibit C.
		d)	Bonus. Consultant acknowledges that the five million (5,000,000) Shares granted to them
pursuant to a letter agreement dated January 13, 2011 constitute a bonus for and in consideration of extraordinary past service
by Consultant .



		e)	Benefits, Other Consideration. No benefits, vacation pay, or other consideration or remuneration
of any kind shall be owed to Consultant by the Client, unless specifically referenced herein.



		f)	Reimbursement of Expenses. The Client shall reimburse all expenses incurred by Consultant
in the performance of the Services, provided that any such expenses in excess of $750 shall require the prior, written authorization
of the Client.



 


7) Client Representations and Warranties.
The Client hereby represents and warrants, knowing that Consultant is relying thereon, that:


 


		a)	The Client is duly organized, validly existing and in good standing under the laws of the state
of Delaware. The Client is qualified to do business as a foreign corporation in each state in which its business requires it to
be so qualified.



		b)	Upon receipt of the full exercise price, where applicable, all shares issued to Consultant under
the Option will be duly and validly issued, fully paid and non-assessable, and will be delivered free and clear of any liens, claims
or encumbrances, except for restrictions imposed by reference to the registration requirements of the Securities Act of 1933.



 


8) Consultant Representations. Consultant
hereby represents, knowing that the Client is relying thereon, that:


 


		a)	Consultant is an Accredited Investor, as that term is defined in Regulation D in the Securities
Act, 1933, and Consultant has completed the attached Exhibit D, or, in lieu of this, Consultant agrees that the Option and Shares
shall only be issued immediately if and when an appropriate exemption from registration exists or an effective registration statement
is available;



		b)	Consultant has not in the past, nor will he in the future engage in any activity contrary to the
securities laws of any jurisdiction including, without limitation, those of the United States of America; and
	 	c)	Consultant has read and accepted the Viral Genetics Intellectual Property Agreement, attached hereto as Exhibit E, which
is part of this Agreement and the provisions of which shall survive the expiration or earlier termination of this Agreement in
strict accordance with the time periods as described therein.






 






    	3



    	 



    

 


9)Changes to Common Stock.
In the event that the Client shall undertake a recapitalization, reverse stock split, forward stock split, reclassification, or
other change to its common stock (a "Change in Common Stock Properties"), the quantity of Shares which may be acquired
through exercise of any delivered but unexercised options or undelivered options, and the exercise price payable thereto shall
be increased or decreased proportionately, in accordance with the terms of said Change in Common Stock Properties.


 


10)Extension and Renewal. The
Term may be extended or renewed, and this Agreement may be amended, only by the written agreement of the parties.


 


11)Indemnification.


 


		a)	The Client hereby indemnifies and defends the Consultant and each of her executors, heirs, assigns,
and representatives, as applicable, (each, an "Indemnitee") against, and holds each Indemnitee harmless from, any loss,
liability, obligation, deficiency, damage or expense including, without limitation, interest, penalties, reasonable attorneys'
fees and disbursements (collectively, "Damages"), that any Indemnitee may suffer or incur based upon, arising out of,
relating to or in connection with (whether or not in connection with any third party claim):



		i)	any
breach of any representation or warranty made by the Client contained in this Agreement;



		ii)	the
failure of the Client to perform or to comply with any covenant or condition required to be performed or complied with in accordance
with this Agreement; and
	 	iii)	the good faith
performance of the Services.






		b)	Indemnification Procedures for Third Party Claims.



		i)	Promptly
after notice to an Indemnitee of any claim or the commencement of any action or proceeding, including any actions or proceedings
by a third party (hereafter referred to as "Proceeding" or "Proceedings"), involving any Damage referred to
in this Section, such Indemnitee shall, if a claim for indemnification in respect thereof is to be made against an Indemnitee
pursuant to this Section, give written notice to the Client, setting forth in reasonable detail the nature thereof and the basis
upon which such party seeks indemnification hereunder; provided, however, that the failure of any Indemnitee to give such notice
shall not relieve the Client of its obligations hereunder, except to the extent that the Client is actually prejudiced by the
failure to give such notice.



		ii)	In
the case of any Proceeding by a third party against an Indemnitee, the Client shall, upon notice as provided above, assume the
defense thereof, with counsel reasonably satisfactory to the Indemnitee, and, after notice from the Client to the Indemnitee of
its assumption of the defense thereof, the Client shall not be liable to such Indemnitee for any legal or other expenses subsequently
incurred by the Indemnitee in connection with the defense thereof (but the Indemnitee shall have the right, but not the obligation,
to participate at its own cost and expense in such defense by counsel of its own choice) or for any amounts paid or foregone by
the Indemnitee as a result of any settlement or compromise thereof that is effected by the Indemnitee (without the written consent
of the Client).



		iii	Anything
in this Section 12 notwithstanding, if both the Client and the Indemnitee are named as parties or subject to such Proceeding and
either party determines with advice of counsel that there may be one or more legal defenses available to it that are different
from or additional to those available to the other party or that a material conflict of interest between such parties may exist
in respect of such Proceeding, then the Client may decline to assume the defense on behalf of the Indemnitee or the Indemnitee
may retain the defense on its own behalf, and, in either such case, after notice to such effect is duly given hereunder to the
other party, the Client shall be relieved of its obligation to assume the defense on behalf of the Indemnitee, but shall be required
to pay any legal or other expenses including, without limitation, reasonable attorneys' fees and disbursements, incurred by the
Indemnitee in such defense.



 






    	4



    	 



    

 





	 	iv)	If the Client assumes the defense
of any such Proceeding, the Indemntiee shall cooperate fully with the Client and shall appear and give testimony, produce documents
and other tangible evidence, and otherwise assist the Client in conducting such defense. The Client shall not, without the consent
of the Indemnitee, consent to entry of any judgment or enter into any settlement or compromise which does not include as an unconditional
term thereof the giving by the claimant or plaintiff to such Indemnitee of a release from all liability in respect of such claim
or Proceeding. Provided that proper notice is duly given, if the Client shall fail promptly and diligently to assume the defense
thereof, then the Indemnitee may respond to, contest and defend against such Proceeding and may make in good faith any compromise
or settlement with respect thereto, and recover from the Client the entire cost and expense thereof including, without limitation,
reasonable attorneys' fees and disbursements and all amounts paid or foregone as a result of such Proceeding, or the settlement
or compromise thereof. The indemnification required hereunder shall be made by periodic payments of the amount thereof during
the course of the investigation or defense, as and when bills or invoices are received or loss, liability, obligation, damage
or expense is actually suffered or incurred.



		c)	The
provisions of this Section 12 shall survive the expiration or earlier termination of this Agreement.







 


12. Termination. Except where due to the death
of Consultant, Client may not terminate this Agreement during its term without cause. Consultant may terminate this agreement at
any time during the term hereof. As used herein, cause shall mean that:


 


(a)Consultant has
materially breached in a manner injurious to the Client the terms of this Agreement (other than as described in subparagraphs (b)
and (c) of this paragraph 13), and such breach has not been cured within 30 days following the date of written notice to Consultant
of such breach;


(b)Consultant has
been grossly negligent in the performance of her duties at least three times in any consecutive 90-day period;


(c)Consultant has
engaged in material and willful or gross misconduct in the performance of her duties hereunder;


(d)Consultant
is convicted or pleads nolo contendre with respect to any criminal offense other than misdemeanor traffic violations;


(e)Consultant violates
the Client's Code of Ethics, or such other governance standards as are adopted by the Client from time to time; or


(f)Consultant
is found by a court of competent jurisdiction to have committed any act or engaged in any conduct that is fraudulent, or Consultant
becomes the subject of a civil or criminal proceeding or investigation relating to securities fraud, including, without limitation,
proceedings initiated by the National Association of Securities Dealers, and the United States Securities and Exchange Commission.


 






    	5



    	 



    

 


13. Termination Payment.


 


(a)In the event that the
Consultant's engagement is terminated (i) by the Client for reasons other than cause as defined in paragraph 12, or (ii) is terminated
by Consultant for good reason (as hereinafter defined), the Consultant shall be compensated by the Client through (x) a single
sum payment due within 30 days after such termination in an amount equal to the monthly Fees provided for in paragraph 6(a) above
in effect as of the date of termination multiplied by twelve (12) and payable in cash or, at Consultant's election, in stock as
determined under Section 6(a) above, and (y) the minimum number of all options that would be due to Consultant during the Initial
Term had the Agreement not been terminated or, in the case of a subsequent one-year extension, the Annual Option due for that year,
provided that the exercise price of all such options shall be determined using the VWAP as of the effective date of termination.


 


(b)In the event that the
Consultant's engagement is terminated by the Consultant at any time during the term hereof for any reason other than good reason
or is terminated by the Client during the term hereof for cause as provided in paragraph 12, Consultant shall be entitled to receive
only that compensation due and payable hereunder with respect to periods ended on or before the date of termination including options
for the current year.


 


(c)As used in this Agreement, termination
for "good reason" shall mean termination by the Consultant in the following circumstances: (i) a material breach by Client
of this Agreement, and such breach has not been cured within 30 days following the date of written notice to Client of such breach;
(ii) any "person", including a "group" as determined in accordance with Section 13(d)(3) of the Securities
Exchange Act of 1934 and the Rules and Regulations promulgated thereunder (other than the Client, a subsidiary of the Client, or
Affiliates of the Client as of the date affixed hereof, as that term is promulgated by the Securities and Exchange Commission)
is or becomes, through one or a series of related transactions or through one or more intermediaries, the beneficial owner, directly
or indirectly, of securities of the Client representing 50.1 percent or more of the combined voting power of the then outstanding
securities of the Client; or (iii) any merger or reorganization of the Client whether or not another entity is the survivor, pursuant
to which the holders of all of the shares of the Client outstanding prior to the transaction hold, as a group, less than 50.1 percent
of the combined voting power of the Client or any successor company outstanding after the transaction.


 


14)Cooperation. The parties
shall deal with each other in good faith, good faith meaning honesty in fact and the observance of all commercial standards of
fair dealing and usages of trade, which are regularly observed within the industry.


 


15)No Strict Construction. The
language used in this Agreement shall be deemed to be the language chosen by the parties hereto to express their mutual intent,
and no rule of strict construction shall be applied against any party.


 


16)Arbitration. Any controversy
or claim arising out of or relating to this contract, or the breach thereof, shall be settled by arbitration administered by the
American Arbitration Association in accordance with its Commercial Arbitration Rules. If the parties agree, there shall be one
arbitrator; otherwise there shall be a panel of three arbitrators. The cost of arbitration shall be borne by the Client. Judgment
upon the reward rendered may be entered in any court having jurisdiction thereof.


 






    	6



    	 



    

 


17)Governing Law and Disputes.
This Agreement shall be governed by the laws of the State of California, without regard to choice of law provisions.


 


18)Waiver. Any party hereto
may waive compliance by the other with any of the terms, provisions and conditions set forth herein; provided, however, that any
such waiver shall be in writing specifically setting forth those provisions waived thereby. No such waiver shall be deemed to constitute
or imply waiver of any other term, provision or condition of this Agreement.


 


19)Severability. If and to the
extent that any court of competent jurisdiction holds any provision or any part thereof of this Agreement to be invalid or unenforceable,
such holding shall in no way affect the validity of the remainder of this Agreement.


 


20)Counterpart and Headings.
This Agreement may be executed in two or more counterparts, each of which shall be deemed an original and all of which together
shall constitute one and the same instrument. All headings in this Agreement are inserted for convenience of reference and shall
not affect its meaning or interpretation.


 


21)Entire Agreement. This Agreement
is and shall be considered to be the only agreement or understanding between the parties hereto with respect to the engagement
of Consultant by the Client. All negotiations, commitments, and understandings acceptable to both parties have been incorporated
herein. No letter, telegram, or communication passing between the parties hereto shall be deemed a part of this Agreement; nor
shall it have the effect of modifying or adding to this Agreement unless it is distinctly stated in such letter, telegram, or communication
that it is to constitute a part of this Agreement and is to be attached as a rider to this Agreement and is signed by the parties
to this Agreement.


 


22)Modification of Contract.
This Agreement cannot be modified by tender, acceptance or endorsement of any instrument of payment, including check. Any words
contained in an instrument of payment modifying this contract, including a waiver or release of any claims, or a statement referring
to paying in full is void. This Agreement can only be modified in a separate writing, other than an instrument of payment, signed
by the parties.


 


23)Enforcement.
Consultant acknowledges that any remedy at law for breach of Exhibit E would be inadequate, acknowledges that the Client would
be irreparably damaged by an actual or threatened breach thereof, and agrees that the Client shall be entitled to an injunction
restraining Consultant from any actual or threatened breach of Exhibit E as well as any further appropriate equitable relief without
any bond or other security being required. The Client may pursue enforcement of Exhibit E by commencing an action at law or in
equity without first pursuing arbitration pursuant to Section 16 of this Agreement. In addition to the foregoing, each of
the parties hereto shall be entitled to any remedies available in equity or by statute with respect to the breach of the terms
of this Agreement by the other party.


 


24)Assignment. The provisions
of this Agreement shall be binding upon and inure to the benefit of the parties hereto, and their respective heirs, legal representatives,
successors and assigns. This Agreement may not be assigned without the consent of the parties; provided, however, that nothing
contained herein shall prevent Consultant from assigning or transferring any of the shares or Options, or the royalties referred
to in Section 6 (c) of this Agreement, to any person or entity in accordance with applicable securities laws and regulations.


 






    	7



    	 



    

 


25) Notices. All notices under this
Agreement shall be in writing and shall be sent by certified or registered first class mail, return receipt requested, or shall
be personally delivered, or sent by an overnight delivery service such as Federal Express, or shall be transmitted by telefax (provided
such telefax message is confirmed by telephonic acknowledgment of receipt or by sending via other authorized means a confirmation
copy of such notice) addressed to the parties at their respective last known business addresses.


 


Agreed to effective the 1st day of January 2011


 


 














	VIRAL GENETICS, INC.	 	M. KAREN NEWELL ROGERS
	 	 	 
	 	 	 
	By: /s/ Haig Keledjian	 	/s/ M. Karen Newell Rogers
	President	 	






 


 



 






    	8



    	 



    

 


EXHIBIT A


 


UNSECURED REVOLVING CREDIT NOTE


 


FOR VALUE RECEIVED, Viral Genetics, Inc.,
whose address is 2290 Huntington Drive, Suite 100, San Marino, California, 91108, ("Borrower"), promises to pay
to or to the order of M. Karen Newell Rogers ("Lender"), and her successors and assigns, in lawful money of the
United States of America, those amounts that are unpaid, due and payable to Lender pursuant to Fees earned under the Consulting
Agreement between Borrower and Lender dated effective January 1, 2011 to which this Note is attached (the "Agreement"),
and which such amounts are tendered hereunder pursuant to Section 6 (a) of the Agreement, without interest. No additional amounts
may be tendered hereunder except for amounts due under the Agreement. This Note, the Agreement and all schedules and exhibits attached
thereto are hereinafter referred to as the Transaction Documents.


 


1.Payment and Advance Terms.


 


		(a)	Payment. Borrower shall pay to Lender the entire principal balance under this Unsecured Revolving Credit Note (the "Note") on or before December 31, 2015 (the "Maturity Date").
                                                            Borrower shall pay all amounts due under this Note in lawful money of the United States of America and without set-off,
                                                            deduction, demand or notice.



 


		(b)	Exchange of Loan Obligation. All or any portion of the then outstanding principal
                                                            of this Note ("Exchanged Amount") may be exchanged for shares of Borrower's common stock ("Shares") at
                                                            the election of the Lender at any time prior to the Maturity Date by Lender giving written notice to Borrower in the form
                                                            attached as Annex A. In exchange for the Exchanged Amount so exchanged, Lender shall receive a number of Shares equal to the
                                                            Exchanged Amount divided by the Exchange Price. The Exchange Price shall be equal to the volume-weighted average closing
                                                            price of the Borrower's common stock for the 20 trading days immediately prior to the date of notice by Lender Date (the
                                                            "Exchange Date") as reported on the NASD OTCBB, Pinksheets, or other market where Borrower's common stock is then
                                                            quoted for trading multiplied by 0.8, provided that in the event no such quoted market exists, the Exchange Price shall be
                                                            determined according to an independent appraisal ratified by the disinterested members of the Borrower's board of directors,
                                                            or if there are no disinterested members then the board acting unanimously. An election made by the Lender to exchange
                                                            amounts owed hereunder for Shares cannot be revoked by Lender without the written consent of Borrower. The Borrower shall
                                                            issue and deliver to the Lender the Shares within 5 business days of receiving notice from Lender. Should such Notice of
                                                            Conversion represent all of the remaining obligations due hereunder, Lender shall deliver to Borrower the original Note
                                                            marked "paid in full."



 


		(c)	Mandatory Conversion. Any unpaid principal due hereunder upon the Maturity Date
                                                            shall automatically be exchanged for Shares upon the terms described in Section 1(b) above using the Maturity Date as
                                                            the Exchange Date, without requiring the additional consent of Lender or Borrower.



 


2.Interest. This Note
shall not bear interest.


 


3.Application of Payments.
Payments will be applied first to any costs and expenses (including reasonable attorneys' fees) incurred by Lender in connection
with the collection of amounts owing pursuant to this Unsecured Revolving Credit Note, and then to reduction of principal. All
payments shall be made to Lender at the above-specified address until receipt of notice from Lender to the contrary.


 






    	9



    	 



    

 


4.Default Rate. Upon
the occurrence of an Event of Default, Lender shall be entitled to receive, and Borrower shall pay to Lender, interest on the
outstanding principal balance and any other advances or charges advanced by Lender at a per annum rate equal to the lesser of
(a) twelve percent (12%), or (b) the maximum interest rate which Borrower may by law pay (the "Default Rate").
The Default Rate shall be computed from the occurrence of the Event of Default until the earlier of the date upon which the Event
of Default is cured or the date upon which due an owing under this Note are paid in full. The preceding sentence, however, shall
not be construed as an agreement or privilege to extend the date of the any payment due hereunder, or as a waiver of any other
right or remedy accruing to Lender by reason of the occurrence of any Event of Default.


 


5.Prepayment. Borrower
shall have the right to prepay this Note in whole or in part by providing 30 calendar days advance written notice to Lender.
During this period and until the end of the 30 day notice period, Lender may at its sole discretion elect to exercise the exchange
rights provided for in Section 1 (b) herein.


 


6.Security Interest.
This Note is Unsecured.


 


7.Default. Any one
of the following occurrences shall constitute an "Event of Default" under this Unsecured Revolving Credit
Note provided that Lender shall be required to give written notice of same:


 


		(a)	The failure of Borrower to repay all outstanding principal on or before the Maturity
                                                            Date;



 


		(b)	The failure of Borrower to promptly perform any obligation of Borrower under or the
                                                            existence of an Event of Default as defined in any Transaction Document within thirty (30) days of notice from Lender;
                                                            or



 


		(c)	Borrower becomes insolvent, bankrupt or generally fails to pay its debts as such debts
                                                            become due; is adjudicated insolvent or bankrupt; admits in writing its inability to pay its debts; or shall suffer a
                                                            custodian, receiver or trustee for it or substantially all of its property to be appointed and if appointed without its
                                                            consent, not be discharged within sixty (60) consecutive days; makes an assignment for the benefit of creditors; or suffers
                                                            proceedings under any law related to bankruptcy, insolvency, liquidation or the reorganization, readjustment or the release
                                                            of debtors to be instituted against it and if contested by it not dismissed or stayed within sixty (60) consecutive days; if
                                                            proceedings under any law related to bankruptcy, insolvency, liquidation, or the reorganization, readjustment or the release
                                                            of debtors is instituted or commenced by or against Borrower; if any order for relief is entered relating to any of the
                                                            foregoing proceedings; if Borrower shall call a meeting of its creditors with a view to arranging a composition or adjustment
                                                            of its debts; or if Borrower shall by any act or failure to act indicate its consent to, approval of or acquiescence in any
                                                            of the foregoing.



 






    	10



    	 



    

 


8.Remedies.
Upon the happening and during the continuation of any Event of Default, (i) Lender may, at its sole option, declare the
entire principal immediately due and payable in full; (ii) interest shall accrue on all amounts due hereunder at the Default Rate
until paid in full or such Event of Default is cured; and (iii) Lender shall have and may exercise any and all rights and remedies
available hereunder, at law and in equity, together with any and all rights and remedies provided in any Transaction Document.
The acceptance of any installment or payment after the occurrence of an Event of Default or event giving rise to the right of
acceleration provided for herein shall not constitute a waiver of such right of acceleration with respect to such Event of Default
or event or any subsequent Event of Default. The remedies of Lender, as provided herein or in any Transaction Document, shall
be cumulative and concurrent, and may be pursued singularly, successively or together, at the sole discretion of Lender, and may
be exercised as often as occasion therefore shall arise. Any act, omission or commission of Lender, including, specifically, any
failure to exercise any right, remedy or recourse, shall be released and be effected only through a written document executed
by Lender and then only to the extent specifically recited therein. A waiver or release with reference to any one event shall
not be construed as continuing, as a bar to, or as a waiver or release of, any subsequent right, remedy or recourse as to a subsequent
event.


 


 9. Collection Costs. If one or more Events of Default (or any event which with notice or passage of time or both would constitute an Event of Default) hereunder shall occur and continues, Borrower promises to pay all collection costs, including but not limited to all reasonable attorneys' fees, court costs, and expenses of every kind, incurred by Lender in connection with such collection or the protection or enforcement of any or all of the security for this Unsecured Revolving Credit Note, whether or not any lawsuit is filed with respect thereto (including costs and reasonable attorneys' fees on any appeals or in any bankruptcy proceedings).


 




 10. Miscellaneous.


 




		(a)	Successors and Assigns. This Note inures to the benefit of Lender and its successors or assigns, and binds Borrower, and its respective permitted successors and assigns, and the words
                                                            "Lender" and "Borrower" whenever occurring herein shall be deemed and construed to include such
                                                            respective successors and assigns.



 


		(b)	Severability. Any term or provision of this Note that is held by a court of competent jurisdiction or other authority to be invalid, void or unenforceable in any situation or in any jurisdiction shall
                                                            not affect the validity or enforceability of the remaining terms and provisions or the validity or enforceability of the
                                                            invalid, void or unenforceable term or provision in any other situation or in any other jurisdiction. If the final judgment
                                                            of a court of competent jurisdiction or other authority declares that any term or provision of this Note is invalid, void or
                                                            unenforceable, the parties agree that the court making such determination shall have the power to and shall, subject to the
                                                            discretion of such court, reduce the scope, duration, area or applicability of the term or provision, to delete specific
                                                            words or phrases, or to replace any invalid, void or unenforceable term or provision with a term or provision that is valid
                                                            and enforceable and that comes closest to expressing the intention of the invalid or unenforceable term or provision.



 


		(c)	Waiver. To the fullest extent permitted by law, Borrower hereby waives all valuation and appraisement privileges, presentment and demand for payment, protest, notice of protest and nonpayment,
                                                            dishonor and notice of dishonor, bringing of suit, lack of diligence or delays in collection or enforcement of this Note and
                                                            notice of the intention to accelerate, the release of any liable party, the release of any security for the indebtedness
                                                            evidenced hereby, and any other indulgence or forbearance, and is and shall be directly and primarily liable for the amount
                                                            of all sums owing and to be owed hereon, and agrees that this Note and any or all payments coming due hereunder may be
                                                            extended or renewed from time to time without in any way affecting or diminishing Borrower's liability hereunder.



 






    	11



    	 



    

 


		(d)	Notices. All notices required to be given to any of the parties hereunder shall be in writing and shall be delivered (a) by personal delivery, with receipt acknowledged; (b) by telecopier or electronic mail
                                                            (with original copy to follow as set forth herein); (c) by reputable overnight commercial courier service; or (d) by United
                                                            States registered or certified mail, return receipt requested, postage prepaid, to the parties at the addresses as set forth
                                                            at the first of this Note (subject to the right of a party to designate a different address for itself by notice similarly
                                                            given). Whenever the giving of notice is required, the giving of such notice may be waived in writing by the party entitled
                                                            to receive such notice.



 


		(e)	Entire Agreement. This Note (together with the Transaction Documents) contains
                                                            the entire agreement between the parties with respect to the subject matter hereof and thereof.



 


		(f)	Modification of Agreement. This Note may not be modified, altered or amended,
                                                            except by an agreement in writing signed by both Borrower and Lender.



 


		(g)	Releases by Borrower. Borrower hereby releases Lender from all technical and procedural errors, defects and imperfections whatsoever in enforcing the remedies available to Lender upon a default by
                                                            Borrower hereunder.



 


		(h)	Remedies Not Exclusive. No remedy herein conferred upon or reserved to Lender is
                                                            intended to be exclusive of any other remedy or remedies available to Lender under this Unsecured Revolving Credit Note, at
                                                            law, in equity or by statute, and each and every such remedy shall be cumulative and in addition to every other remedy
                                                            given hereunder or now or hereafter existing at law, in equity or by statute.



 


		(i)	Governing Law. This Note shall be governed by and construed under the laws of the
                                                            State of California without giving effect to the choice of law provisions thereof.



 


		(j)	Consent to Jurisdiction. Borrower hereby consents that any action or proceeding
                                                            against it may be commenced and maintained in any Federal or state court sitting in Los Angeles County, California, and that
                                                            such courts shall have jurisdiction with respect to the subject matter hereof and the person of Borrower and the
                                                            collateral securing Borrower's obligations hereunder.



 


		(k)	Time of Essence. Time is of the essence of this Note and all of the obligations hereunder.



 


		(l)	Headings. The headings of the sections of this Note are inserted for convenience only and do not constitute a part of this Unsecured Revolving Credit Note.



 






    	12



    	 



    

 


		(m)	Waiver of Jury Trial. BORROWER AND LENDER, TO THE FULL EXTENT PERMITTED BY LAW,
                                                            EACH HEREBY KNOWINGLY, INTENTIONALLY AND VOLUNTARILY WAIVES, RELINQUISHES AND FOREVER FORGOES HEREBY THE RIGHT TO A TRIAL BY
                                                            JURY IN ANY ACTION OR PROCEEDING, INCLUDING, WITHOUT LIMITATION, ANY TORT ACTION, BROUGHT BY EITHER OF THEM AGAINST THE OTHER
                                                            BASED UPON, ARISING OUT OF, OR IN ANY WAY RELATING TO OR IN CONNECTION WITH THIS UNSECURED REVOLVING CREDIT NOTE, OR ANY
                                                            COURSE OF CONDUCT, ACT, OMISSION, COURSE OF DEALING, STATEMENTS (WHETHER VERBAL OR WRITTEN) OR ACTIONS OF ANY PERSON
                                                            (INCLUDING, WITHOUT LIMITATION, SUCH PERSON'S
DIRECTORS, OFFICERS, PARTNERS, MEMBERS, EMPLOYEES, AGENTS OR ATTORNEYS, OR ANY OTHER PERSONS AFFILIATED WITH SUCH PERSON), IN CONNECTION
WITH THIS NOTE, INCLUDING, WITHOUT LIMITATION, IN ANY COUNTERCLAIM WHICH BORROWER MAY BE PERMITTED TO ASSERT HEREUNDER OR WHICH
MAY BE ASSERTED BY LENDER OR ITS AGENTS AGAINST BORROWER, WHETHER SOUNDING IN CONTRACT, TORT OR OTHERWISE. THIS WAIVER BY BORROWER
OF ITS RIGHT TO A JURY TRIAL IS A MATERIAL INDUCEMENT FOR LENDER UNDER THIS UNSECURED REVOLVING CREDIT NOTE.



 





		(n)	Note for Business or Commercial Purpose. BORROWER EXPRESSLY WARRANTS AND
                                                            REPRESENTS TO LENDER THAT THIS NOTE IS INTENDED FOR AND WILL BE USED FOR A BUSINESS OR COMMERCIAL PURPOSE AND THAT THIS NOTE
                                                            IS NOT INTENDED FOR A CONSUMER, PERSONAL, FAMILY OR HOUSEHOLD PURPOSE.



 


		(o)	Authority. Borrower (and the undersigned representative of Borrower, if any) represents and warrants that it has full power and authority to execute and deliver this Note , and the execution and
                                                            delivery of this Note has been duly authorized and does not conflict with or constitute a default under any law, judicial
                                                            order or other agreement affecting Borrower.



 


		(p)	Assignment. Lender may assign, transfer, pledge or hypothecate any or all of this Note or the Shares acquirable upon exchange without Borrower's consent.



 


IN WITNESS WHEREOF, Borrower has
executed and delivered this Note effective as of the date first above written.


 


 


BORROWER:


 


VIRAL GENETICS, INC.


 


 


 


 


 


By   /s/ Haig
Keledjian                    


  Haig Keledjian, President and CEO


 






    	13



    	 



    

 


ANNEX A


 


NOTICE OF CONVERSION


 


The undersigned hereby elects to convert
principal of the Note pursuant to Section 1(b) therein into shares of common stock, par value $0.0001 per share, of Viral Genetics,
Inc., a Delaware corporation ("Shares"), according to the conditions hereof, as of the date written below. If Shares
are to be issued in the name of a person other than the undersigned, the undersigned will pay all transfer taxes payable with respect
thereto and is delivering herewith such certificates and opinions as reasonably requested by the Company in accordance therewith.
No fee will be charged to the holder for any conversion, except for such transfer taxes, if any.


 


Conversion calculations:


 


Date to Effect Conversion:


 


Principal Amount of Note to be Converted:


 


Number of shares of Common Stock to be issued:


 


 


 


Signature:


 


Name:


 


Address:


 






    	14



    	 



    

 


EXHIBIT B


VIRAL GENETICS, INC.


 


Option
for the Purchase of

Shares of Common Stock

Par Value $0.0001 


 


STOCK OPTION AGREEMENT


 


THE HOLDER OF THIS OPTION, BY ACCEPTANCE
HEREOF, BOTH WITH RESPECT TO THE OPTION AND COMMON STOCK ISSUABLE UPON EXERCISE OF THE OPTION, AGREES AND ACKNOWLEDGES THAT THE
SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE "SECURITIES
ACT"), OR UNDER THE SECURITIES LAWS OF ANY STATE. THESE SECURITIES HAVE BEEN ACQUIRED FOR INVESTMENT AND MAY NOT BE TRANSFERRED
OR SOLD IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT OR OTHER COMPLIANCE UNDER THE SECURITIES ACT OR THE LAWS OF THE APPLICABLE
STATE OR A "NO ACTION" OR INTERPRETIVE LETTER FROM THE SECURITIES AND EXCHANGE COMMISSION OR AN OPINION OF COUNSEL REASONABLY
SATISFACTORY TO THE ISSUER, AND ITS COUNSEL, TO THE EFFECT THAT THE SALE OR TRANSFER IS EXEMPT FROM REGISTRATION UNDER THE SECURITIES
ACT AND SUCH STATE STATUTES.


 


This is to certify
that, for value received, M. Karen Newell Rogers (the "Optionee") is entitled to purchase from VIRAL GENETICS, INC.
(the "Company" or "Corporation"), on the terms and conditions hereinafter set forth, all or any part of
10,000,000 shares ("Option Shares") of the Company's common stock, par value $0.0001 (the "Common Stock"),
at an exercise price per share equal to the volume weighted average price for the twenty (20) trading days immediately following
the actual date of execution of the Agreement to which this Exhibit B is attached ("Option Price"). Upon exercise of
this option in whole or in part, a certificate for the Option Shares so purchased shall be issued and delivered to the Optionee.
If less than the total option is exercised, a new option of similar tenor shall be issued for the unexercised portion of the options
represented by this Agreement.


 


This option is granted subject to the following further
terms and conditions:


 


1. This option shall
vest immediately. The right to exercise this option with respect to any of the Option Shares shall terminate on December 31, 2018.
In order to exercise this option with respect to all or any part of the Option Shares for which this option is at the time exercisable,
Optionee (or in the case of exercise after Optionee's death, Optionee's executor, administrator, heir or legatee, as the case may
be) must take the following actions:


 


(a)Deliver to the
Corporate Secretary of the Corporation an executed notice of exercise in substantially the form of that attached to this Agreement
(the "Exercise Notice") in which there is specified the number of Option Shares which are to be purchased under the exercised
option.


 


(b)Pay the aggregate Option
Price for the purchased shares through one or more of the following alternatives:


 


		(i)	full payment in cash or by check made payable
to the Corporation's order;



 






    	15



    	 



    

 


		(ii)	full payment in shares of Common Stock valued at Fair Market Value on the
Exercise Date (as such term is defined below);



 


		(iii)	full payment through a combination of shares of Common Stock valued at Fair Market Value on the
Exercise Date and cash or check payable to the Company's order;



 


		(iv)	full payment effected through a broker-dealer sale and remittance procedure pursuant to which Holder
shall provide concurrent irrevocable written instructions (i) to a brokerage firm to effect the immediate sale of the purchased
shares and remit to the Company, out of the sale proceeds available on the settlement date, sufficient funds to cover the aggregate
Option Price payable for the purchased shares and (ii) to the Company to deliver the certificates for the purchased shares directly
to such brokerage firm in order to complete the sale transaction; or



 


		(v)	full payment through conversion of this warrant to purchase Option Shares into the number of
fully paid and nonassessable Option Shares calculated pursuant to the following formula:



 


X = Y (A-B)


A


where:


 


X=the number of Option Shares to be issued
to the Holder;


 


Y=the number of Option Shares for which the
conversion right is being exercised;


 


A=the Fair Market Value per share as of the
last business day immediately preceding the


date of exercise of such conversion right; and


 


B=the Option Price with respect to such Option
Shares.


 


(c)Furnish to the
Corporation appropriate documentation that the person or persons exercising the option (if other than Optionee) have the right to exercise this option.


 


(d)For purposes
of this Agreement, the Exercise Date shall be the date on which the executed Exercise Notice shall have been delivered to the Company. Except to the extent the sale and remittance procedure specified
above is utilized in connection with the option exercise, payment of the Option Price for the purchased shares must accompany such
Exercise Notice.


 


(e)Upon such exercise,
the Company shall issue and cause to be delivered with all reasonable dispatch (and in any event within three business days of
such exercise) to or upon the written order of the Optionee at its address, and in the name of the Optionee, a certificate or
certificates for the number of full Option Shares issuable upon the exercise together with such other property (including cash)
and securities as may then be deliverable upon such exercise. Such certificate or certificates shall be deemed to have been issued
and the Optionee shall be deemed to have become a holder of record of such Option Shares as of the Exercise Date.


 






    	16



    	 



    

 


(f)For all valuation
purposes under this Agreement, the Fair Market Value per share of Common Stock on any relevant date shall be the closing selling
price per share on the date in question on the securities exchange or market in which the shares are listing for trading, as such
price is officially quoted by such exchange. If there is no reported sale of Common Stock on such exchange on the date in question,
then the Fair Market Value shall be the closing selling price on the exchange or market on the last preceding date for which such
quotation exists.


 


2.The Optionee
acknowledges that the shares subject to this option have not and will not be registered as of the date of exercise of this option
under the Securities Act or the securities laws of any state. The Optionee acknowledges that this option and the shares issuable
on exercise of the option, when and if issued, are and will be "restricted securities" as defined in Rule 144 promulgated
by the Securities and Exchange Commission and must be held indefinitely unless subsequently registered under the Securities Act
and any other applicable state registration requirements. The Company is under no obligation to register the securities under the
Securities Act or under applicable state statutes. In the absence of such a registration or an available exemption from registration,
sale of the Option Shares may be practicably impossible. The Optionee shall confirm to the Company the representations set forth
above in connection with the exercise of all or any portion of this option. Optionee shall have piggyback registration rights with
management and Affiliates of the Company.


 


3.The Company,
during the term of this Agreement, will obtain from the appropriate regulatory agencies any requisite authorization in order to
issue and sell such number of shares of its Common Stock as shall be sufficient to satisfy the requirements of the Agreement.


 


4.The number of
Option Shares purchasable upon the exercise of this option and the Option Price per share shall be subject to adjustment from time
to time subject to the following terms. If the outstanding shares of Common Stock of the Company are increased, decreased, changed
into or exchanged for a different number or kind of shares of the Company through reorganization, recapitalization, reclassification,
stock dividend, stock split or reverse stock split, the Company or its successors and assigns shall make an appropriate and proportionate
adjustment in the number or kind of shares, and the per-share Option Price thereof, which may be issued to the Optionee under this
Agreement upon exercise of the options granted under this Agreement. The purchase rights represented by this option shall not be
exercisable with respect to a fraction of a share of Common Stock. Any fractional shares of Common Stock arising from the dilution
or other adjustment in the number of shares subject to this option shall rounded-up to the nearest whole share.


 


5.The Company covenants
and agrees that all Option Shares which may be delivered upon the exercise of this option will, upon delivery, be free from all
taxes, liens, and charges with respect to the purchase thereof; provided, that the Company shall have no obligation with respect
to any income tax liability of the Optionee and the Company may, in its discretion, withhold such amount or require the Optionee
to make such provision of funds or other consideration as the Company deems reasonably necessary to satisfy any income tax withholding
obligation under federal or state law.


 


6.The Company agrees
at all times to reserve or hold available a sufficient number of shares of Common Stock to cover the number of Option Shares issuable
upon the exercise of this and all other options of like tenor then outstanding.


 






    	17



    	 



    

 


7.This option shall
not entitle the holder hereof to any voting rights or other rights as a shareholder of the Company, or to any other rights whatsoever, except the rights herein expressed, and no dividends shall be payable
or accrue in respect of this option or the interest represented hereby or the Option Shares purchasable hereunder until or unless,
and except to the extent that, this option shall be exercised.


 


8.The Company may
deem and treat the registered owner of this option as the absolute owner hereof for all purposes and shall not be affected by any notice to the contrary.


 


9.In the event
that any provision of this Agreement is found to be invalid or otherwise unenforceable under any applicable law, such invalidity or unenforceability shall not be construed as rendering any other provisions
contained herein invalid or unenforceable, and all such other provisions shall be given full force and effect to the same extent
as though the invalid or unenforceable provision were not contained herein.


 


10.This Agreement
shall be governed by and construed in accordance with the internal laws of the state of California, without regard to the principles of conflicts of law thereof.


 


11.Except as otherwise
provided herein, this Agreement shall be binding on and inure to the benefit of the Company and the person to whom an option is granted hereunder, and such person's heirs, executors, administrators,
legatees, personal representatives, assignees, and transferees.


 


IN WITNESS WHEREOF,
the Company has caused this option to be executed on the ~~day of January 2011 by the signature of its duly authorized officer.


VIRAL GENETICS, INC.


 


 


By  /s/                                       


Duly Authorized Officer


 


The undersigned Optionee
hereby acknowledges receipt of a copy of the foregoing option and acknowledges and agrees to the terms and conditions set forth
in the option.


 


/s/ M. Karen Newell Rogers                   


M. Karen Newell Rogers


 






    	18



    	 



    

 


Exercise Notice


(to be signed only upon exercise of Option)


 


TO:Viral Genetics, Inc.


 


The Optionee, holder
of the attached option, hereby irrevocable elects to exercise the purchase rights represented by the option for, and to purchase
thereunder, __________________________ shares of common stock of Viral Genetics, Inc., and herewith makes payment therefor, and
requests that the certificate(s) for such shares be delivered to the Optionee at:


 











 







 







 






If
acquired without registration under the Securities Act of 1933, as amended ("Securities Act"), the Optionee represents
that the Common Stock is being acquired without a view to, or for, resale in connection with any distribution thereof without registration
or other compliance under the Securities Act and applicable state statutes, and that the Optionee has no direct or indirect participation
in any such undertaking or in the underwriting of such an undertaking. The Optionee understands that the Common Stock has not been
registered, but is being acquired by reason of a specific exemption under the Securities Act as well as under certain state statutes
for transactions by an issuer not involving any public offering and that any disposition of the Common Stock may, under certain
circumstances, be inconsistent with these exemptions. The Optionee acknowledges that the Common Stock must be held and may not
be sold, transferred, or otherwise disposed of for value unless subsequently registered under the Securities Act or an exemption
from such registration is available. The Company is under no obligation to register the Common Stock under the Securities Act,
except as provided in the Agreement for the option. The certificates representing the Common Stock will bear a legend restricting
transfer, except in compliance with applicable federal and state securities statutes.


 


The Optionee agrees
and acknowledges that this purported exercise of the option is conditioned on, and subject to, any compliance with requirements
of applicable federal and state securities laws deemed necessary by the Company.


 


DATED
this ______ day of _____________________, _________.


 



 





Signature


 






    	19



    	 



    

 


EXHIBIT C


 


Definitions for Royalty Calculation


 


"Net Sales" shall mean the total gross receipts for
sales of Licensed Products or practice of Licensed Processes by or on behalf of Viral Genetics or its Affiliates, and from leasing,
renting, or otherwise making Licensed Products available to others without sale or other dispositions, whether invoiced or not,
less returns and allowances, packing costs, insurance costs, freight out, taxes or excise duties imposed on the transaction (if
separately invoiced and paid), and wholesaler and cash discounts in amounts customary in the trade to the extent actually granted.
No deductions shall be made for commissions, or for the costs of collections. Net Sales
shall also include the fair market value of any non-cash consideration received by Licensee or its Affiliates for the sale, lease,
or transfer of Licensed Products or Licensed Processes.


 


"Patent Rights" shall mean all of the following intellectual
property:


 


		a)	the United States and foreign patents and/or patent applications, provisional patent applications,
and invention disclosures referred to in Section 3 of Exhibit E;



		b)	United States and foreign patents issued from the applications referred to in Section 3 of Exhibit
E and from divisionals and continuations of these applications;



		c)	claims of U.S. and foreign continuation-in-part applications, and of the resulting patents, that
are directed to subject matter specifically described in the U.S. and foreign applications referred to in Section 3 of Exhibit
E;



		d)	claims of all foreign patent applications, and of the resulting patents, that are directed to
subject matter specifically described in the United States patents and/or patent applications described in this Exhibit; and any
reissues of United States patents described in this Exhibit



 


"Licensed Process(es)" shall mean any process,
art, or method that is covered in whole or in part by an issued, unexpired claim or a pending claim contained in the Patent Rights.


 


"Licensed Product(s)" shall mean any:


 


		a)	product or part thereof that is covered in whole or in part by an issued, unexpired claim or a
pending claim contained in the Patent Rights in the country in which any such product or part thereof is made, used or sold; and



		b)	product, apparatus, or part thereof that is manufactured by using a process covered in whole or
in part by an issued, unexpired claim or a pending claim contained in the Patent Rights in the country in which any Licensed Processes
is used.



 


"Affiliate(s)" shall mean every corporation, or entity,
which, directly or indirectly, or through one or more intermediaries, controls, is controlled by, or is under common control with
Viral. For the purposes of this definition, the term "control" means (a) beneficial ownership of at least fifty percent
(50%) of the voting securities of a business organization with voting securities, or (b) a fifty percent (50%) or greater interest
in the net assets or profits of a partnership or business organization without voting securities.


 






    	20



    	 



    

 


EXHIBIT D


 


ACCREDITED INVESTOR QUESTIONNAIRE


 


PERSONAL FINANCIAL INFORMATION. The following information pertaining
to the undersigned as a natural person and U.S. Persons within the meaning of Regulation S is being provided here
in lieu of furnishing a personal financial statement. If correct, please acknowledge category (d) and at least one of categories
(a), (b) and (c).


 


(a)My individual net worth,
or joint net worth with my spouse excluding my primary residence, exceeds $1,000,000.


 


Yes [ ]No [ ]


 


_____ INITIAL


 


(b)My individual income
in 2009 and 2010 exceeded $200,000 in each such year, and I reasonably expect my individual income will be in excess of $200,000
in 2011.


 


Yes [ ]No [ ]


 


_____ INITIAL


 


(c)The joint income of my
spouse and I in 2009 and 2010 exceeded $300,000 in each such year, and I reasonably expect our joint income will be in excess of
$300,000 in 2011.


 


Yes [ ]No [ ]


 


_____ INITIAL


 


(d)Considering the foregoing
and all other relevant factors in my financial and personal circumstances, I am able to bear the economic risk of an investment
in the Client.


 


Yes [ ]No [ ]


 


_____ INITIAL


 


 


 


The foregoing is a true representation of my financial status:


 


/s/ M. Karen Newell Rogers                  


M. KAREN NEWELL ROGERS


 






    	21



    	 



    

 


EXHIBIT E


 


Viral Genetics Intellectual Property
Agreement


 

(the "Viral Genetics IP Agreement")


 


In consideration of Consultant entering into that
certain Consulting Agreement dated as of the date hereof (the "Consulting Agreement") with Viral Genetics, Inc. ("Viral"),
Consultant agrees as follows. Capitalized terms used herein that are not defined in this Viral Genetics IP Agreement shall be defined
as in the Consulting Agreement.


 


1. Non-Solicitation. Consultant acknowledges
that, in the course of performing Services (as used throughout this Viral Genetics IP Agreement as defined in the Consulting Agreement)
for or on behalf of Viral, having access to Viral's technology, reports, processes, materials, knowledge and know-how, data, facilities,
books and records, Consultant may from time to time receive Confidential Information (as defined in Paragraph 2, below) of or with
respect to Viral and hereby stipulates and agrees that such Confidential Information is a part of and essential to the operations
and goodwill of Viral. In connection and in furtherance of the foregoing, Consultant may not (whether directly or indirectly; as
the principal or on such person's own account; or solely or jointly with others as an Consultant, agent, independent contractor,
consultant, general or limited partner, member, stockholder or holder of equity securities of any other person, other than through
ownership of less than one percent of a class of publicly-traded securities of a company) engage in any of the conduct or activity
described below in this Paragraph 1.


 


(a)Consultant may not, so long
as Consultant is a Consultant of Viral pursuant to the Consulting Agreement and until the third anniversary of the effective date
of termination of the Consulting Agreement for any reason, solicit, induce or influence any person that at such time is (or, during
the six (6) month period ending on the effective date of termination of the Consulting Agreement, was) a vendor, licensor, licensee,
distributor, customer, company, Consultant, or independent contractor of Viral, excluding the University, to terminate any contract
or agreement with Viral or leave the service of Viral. Consultant acknowledges that the restrictions in this subparagraph (a) of
this Paragraph 1 will not impair Consultant's ability to carry on Consultant's profession or earn a living.


 


(b)Consultant may not, so long as Consultant
is a Consultant of Viral and until the third anniversary of the effective date of termination of the Consulting Agreement for any
reason, without the express prior written consent of Viral, participate either directly or indirectly in any discussion or negotiation
with any person that at such time is (or, during the six month period ending on the effective date of termination of the Consulting
Agreement, was) a vendor, licensor, licensee, distributor, customer, company, Consultant, or independent contractor of Viral the
purpose of which discussion or negotiation would be materially adverse to the interests of Viral and the relationship existing
between Viral and such person. Consultant acknowledges that the restrictions in this subparagraph (b) of Paragraph 1 will not impair
Consultant's ability to carry on Consultant's profession or earn a living.


 






    	22



    	 



    

 


2. Non-Disclosure of Information. Consultant
understands that the covenants and agreements in this Paragraph 2 may limit Consultant's ability to earn a livelihood in a business
similar to the business of Viral of researching, developing and distributing biomedical products and technology, but nevertheless
believes that Consultant has received and will receive sufficient consideration and other benefits from Viral so as to clearly
justify such restrictions which, in any event (given Consultant's education, skills and ability), Consultant does not believe
would prevent Consultant from earning a living:


 


(a)Consultant acknowledges
that, in the course of performing Services for or on behalf of Viral, having access to Viral's technology, reports, processes,
knowledge and know-how, data, facilities, books and records, or otherwise being associated with Viral, Consultant will have access
to, and become acquainted with, Confidential Information of or with respect to Viral and hereby stipulates and agrees that such
Confidential Information is a part of and essential to the operations and goodwill of Viral. Consultant (i) hereby stipulates and
acknowledges that the Confidential Information constitutes important, material, proprietary and confidential trade secrets of Viral
that affect the successful conduct of the business and goodwill of, Viral; (ii) stipulates and acknowledges that any and all of
the Confidential Information is the sole and exclusive property of Viral, regardless of whether Consultant was engaged in the development
of any of such Confidential Information while performing Services for or on behalf of Viral; (iii) agrees to keep all such Confidential
Information in strictest confidence, and not to, directly or indirectly, use or divulge, disclose or communicate to any person
(other than a duly-authorized representative of Viral) any such Confidential Information other than in the ordinary course of business
of Viral for the benefit of Viral; and (iv) agrees not to copy or otherwise duplicate any such Confidential Information or knowingly
allow anyone else to copy or otherwise duplicate such Confidential Information, other than in the ordinary course of business of
Viral for the benefit of Viral. Upon the termination of the Consulting Agreement, and at any time at the request of Viral, shall
promptly return to Viral all copies of such Confidential Information delivered to or obtained by Consultant or, at the election
of Viral, certify that all copies of such Confidential Information in the possession of Consultant or any person who received such
Confidential Information from Consultant have been destroyed or erased, except that Consultant may keep one (1) copy thereof for
the purpose of complying with the terms of this Agreement.


 


(b)"Confidential Information"
means, with respect to Viral, any technical, financial, or business information (including, without limitation, manuals, forms,
memoranda, reports, journals, data, test results, correspondence, business plans, customer lists, pricing lists, contracts, plans
or specifications, or the like) that may disclose (or may reasonably be expected to disclose) the customs and practices, marketing
methods and data, services and products, methods of doing business, manner of operation, know-how, formulas, technical data or
information, clinical study protocols, patient or biologic information, manufacturing information or know-how, methods, processes,
compounds, and other confidential information, regardless of whether in written, oral, graphic, encoded, encrypted, tangible, or
intangible forms, all of which the Consultant hereby acknowledges constitute "trade secrets" within the meaning of the
Uniform Trade Secrets Act, codified at Sections 3426 et seq. of the California Civil Code.


 






    	23



    	 



    

 


(c)Consultant shall have
no obligation to preserve the confidential or proprietary nature of any information that (i) was already known to Consultant free
of any obligation to keep such information confidential at the time of disclosure of such information; (ii) is or becomes publicly
known through no wrongful act of Consultant; (iii) is rightfully received from a third person having no direct or indirect secrecy
or confidentiality obligation to Viral; (iv) is disclosed to a third person by Viral without restrictions on confidentiality similar
to those contained in this Paragraph 2; (v) is approved for disclosure by written authorization of Viral; (vi) is developed by
Consultant or on Consultant's behalf independently of the information disclosed to Consultant by Viral as shown by written record;
or (vii) Consultant is obligated to produce pursuant to an order of a court of competent jurisdiction or a valid administrative
or Congressional subpoena, provided that Consultant promptly notifies Viral and cooperates reasonably with Viral's efforts to
contest or limit the scope of such order.


 


(d)Except for the assignment provisions as provided
in Section 3 of this Viral Genetics IP Agreement, the provisions of this Paragraph 2 shall apply to Consultant throughout
the term of the Consulting Agreement and continue in perpetuity.


 


3. Assignment of Inventions. Consultant shall
promptly disclose any Consultant Creations (as defined below) to Viral and any such Consultant Creations shall be Viral's sole
property. All original works of authorship that are made by Consultant (in whole or in part, either alone or jointly with others)
during and in the performance of the Services and that are protectable by copyright are "works made for hire" as defined
in the United States Copyright Act (17 U.S.C.A. Section 101). "Consultant Creation(s)" means any idea, concept, discovery,
development, device, design, apparatus, use, machine, practice, process, method, product, composition of matter, improvement,
formula, algorithm, literary or graphical or audiovisual work or sound recording, mask work, or computer program of any kind (whether
or not subject to patent, copyright, trademark, trade secret, mask work right, or similar protection) that relate(s) in any way
to any of Viral's biological or pharmaceutical products under investigation or development from time to time, or any manufacturing
or production know-how, scientific know-how, processes, or procedures pertaining thereto that are made by Consultant, in whole
or in part, either solely or jointly with others, during and in the performance of the Services, provided, however, that Consultant
does not have a pre-existing obligation to assign any such Consultant Creation to the University. Consultant shall promptly notify
Viral in advance or at the earliest reasonable time if any work being performed or proposed by Viral to be performed by Consultant
under this Agreement may give rise to Consultant Creations that may be assignable to University under any agreements.


 


(a)Consultant hereby assigns to Viral, and agrees
to assign to Viral in the future where appropriate, any and all such Consultant Creations, and agrees to cooperate with Viral
in the execution of appropriate instruments assigning and evidencing such assignment and ownership rights of Viral, to the maximum
extent permitted by Section 2870 of the California Labor Code. In order that Viral may perfect and protect its rights to Consultant
Creations as provided hereunder, Consultant agrees that Consultant's obligations regarding assignment of such Consultant Creations
to Viral shall survive termination of Consultant's engagement with Viral for a term of three years following the date of termination
of the Consulting Agreement for any reason.


 






    	24



    	 



    

 


4.Enforcement. Consultant acknowledges
that the covenants and the restrictions contained in this Agreement are necessary and required for the adequate protection of Viral
and are necessary to preserve the goodwill of Viral and the value of its existing Confidential Information, inventions, contracts
and relationships; such covenants relate to matters that are of a special, unique and extraordinary character that give each of
such covenants or restrictions a special, unique and extraordinary value; and, a breach of any such covenant or restriction will
result in loss of goodwill, invasion of property rights of Viral, unfair competition by the breaching party, and other irreparable
harm and damages to Viral, which cannot be adequately compensated by a monetary award. It
is accordingly agreed that Viral or any of its subsidiaries shall be entitled to an injunction or injunctions to prevent breaches
of this Agreement and to enforce specifically the terms and provisions of this Agreement. Nothing in this Agreement shall
be construed as prohibiting Viral from pursuing any other legal or equitable remedies available to Viral for such breach or threatened
breach of any of the provisions of this Agreement (including, without limitation, recovery of all damages from Consultant and an
equitable accounting of all earnings, profits and other benefits arising from such violation).


 


5.Conflict. In the event of any conflict
between any provision in this Agreement and any provision in the Consulting Agreement, the provision(s) in the Consulting Agreement
shall govern.


 


 


AGREED:


 














	 	 	 	 	 
	 	CONSULTANT	 	 	
	 	 	 	 	 
	 	/s/ M. Karen Newell Rogers	 	DATED:	
	 	M. Karen Newell Rogers	 	 	
	 	 	 	 	 
	 	 	 	 	 
	 	VIRAL GENETICS, INC.	 	 	 
	 	 	 	 	 
	 	/s/ Haig Keledjian, President	 	DATED:	 
	 	Haig Keledjian, President	 	 	 
	 	 	 	 	 






 


 




 






    	25